AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000

Acquisition Dividend AI-generated analysis

πŸ“ˆ AbbVie delivered a 646% total return over 10 years, turning $1,000 into $7,464 and more than doubling the S&P 500's price gain.

πŸ’Š Skyrizi sales grew 24.4% to $5.505B in Q2 2026, while Rinvoq rose 24.5% to $2.525B, offsetting Humira's decline.

🀝 The company is pursuing a pending $10.9B acquisition of Apogee Therapeutics to expand its immunology pipeline.

πŸ’° AbbVie's quarterly dividend tripled from $0.57 in 2016 to $1.73 today, providing a forward yield of roughly 2.30%.

⚠️ Humira sales fell 35.9% to $756M in Q2 2026 following the loss of U.S. exclusivity in early 2023.

πŸ“‰ Imbruvica sales dropped 29.4% last quarter, adding pressure on overall revenue replacement strategies.

πŸ’Έ The stock trades above the average analyst target of $283.19 with a trailing P/E of about 120 due to acquisition charges.

πŸ“‰ AbbVie reports negative shareholders' equity, meaning liabilities exceed assets and limiting room for deal missteps.

πŸ‘” Robert A. Michael took over as CEO in 2024 following the company's strategic pivot post-Humira exclusivity loss.

Bullish Signals
  • AbbVie achieved a 646% total return over 10 years, significantly outperforming the S&P 500's 263% price gain.
  • Skyrizi and Rinvoq grew 24.4% and 24.5% respectively in Q2 2026, reaching $5.505B and $2.525B in sales.
  • The quarterly dividend tripled from $0.57 to $1.73 since 2016, offering a forward yield of roughly 2.30%.
  • The pending $10.9B acquisition of Apogee Therapeutics is expected to deepen the immunology pipeline.
Risk Factors
  • Humira sales fell 35.9% to $756M in Q2 2026 after losing U.S. exclusivity in early 2023.
  • Imbruvica dropped 29.4% last quarter, raising concerns about the speed of revenue replacement.
  • The stock trades above the average analyst target of $283.19 with a trailing P/E of about 120.
  • AbbVie has negative shareholders' equity, indicating liabilities exceed assets and limiting financial flexibility.
Full Analysis
AbbVie (ABBV) has delivered a 646% total return over the last decade, turning $1,000 into $7,464 and significantly outperforming the S&P 500's 263% price gain. The company successfully navigated the loss of exclusivity for its flagship drug Humira in early 2023, which saw sales fall 35.9% to $756M in Q2 2026, by relying on strong growth from its replacement pipeline. The core of AbbVie's recent performance is driven by Skyrizi and Rinvoq, which grew 24.4% and 24.5% respectively in Q2 2026 to reach $5.505B and $2.525B in sales. The company also benefits from its $63B Allergan acquisition, which added Botox and Vraylar, and a pending $10.9B acquisition of Apogee Therapeutics designed to deepen its immunology pipeline. AbbVie offers a robust income profile with a quarterly dividend that tripled from $0.57 in 2016 to $1.73 today, resulting in a forward annual yield of roughly 2.30%. While the stock trades above the average analyst target of $283.19 and carries a high trailing P/E of 120 due to acquisition charges, the forward P/E is more reasonable at 18. Investors face risks regarding further declines in Humira and Imbruvica sales, as well as negative shareholders' equity. Analysts note that future optimism depends on Skyrizi and Rinvoq maintaining mid-20% growth rates and the successful integration of Apogee. The primary concern remains whether these new drugs can fully offset the rapid erosion of Humira and Imbruvica revenues, particularly as Imbruvica dropped 29.4% in the last quarter.